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Fluorescence-Reported Allelic Exchange
Mutagenesis Reveals a Role for
Chlamydia trachomatis TmeA in Invasion
That Is Independent of Host AHNAK
M. J. McKuen,c K. E. Mueller,a Y. S. Bae,b K. A. Fieldsa
Department of Microbiology, Immunology & Molecular Genetics, University of Kentucky College of Medicine,
Lexington, Kentucky, USAa; Department of Life Science, Ewha Womans University, Seoul, South Koreab;
Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami,
Florida, USAc
ABSTRACT Development of approaches to genetically manipulate Chlamydia is fos-
tering important advances in understanding pathogenesis. Fluorescence-reported al-
lelic exchange mutagenesis (FRAEM) now enables the complete deletion of specific
genes in C. trachomatis L2. We have leveraged this technology to delete the coding
sequences for a known type III effector. The evidence provided here indicates that
CT694/CTL0063 is a virulence protein involved in chlamydial invasion. Based on our
findings, we designate the gene product corresponding to ct694-ctl0063 translocated
membrane-associated effector A (TmeA). Deletion of tmeA did not impact develop-
ment of intracellular chlamydiae. However, the absence of TmeA manifested as a de-
crease in infectivity in both tissue culture and murine infection models. The in vitro
defect was reflected by impaired invasion of host cells. TmeA binds human AHNAK,
and we demonstrate here that AHNAK is transiently recruited by invading chlamyd-
iae. TmeA, however, is not required for endogenous AHNAK recruitment. TmeA also
impairs AHNAK-dependent actin bundling activity. This TmeA-mediated effect likely
does not explain impaired invasion displayed by the tmeA strain of Chlamydia, since
AHNAK-deficient cells revealed no invasion phenotype. Overall, our data indicate the
efficacy of FRAEM and reveal a role of TmeA during chlamydial invasion that mani-
fests independently of effects on AHNAK.
KEYWORDS cytoskeleton, invasion, type III secretion, AHNAK
Chlamydia trachomatis remains the leading agent of bacterial sexually transmitteddisease in the United States (serovars D to K) (1) and the leading cause of
preventable blindness globally (serovars A to C) (2). Chlamydiae are Gram-negative
bacteria that preferentially infect mucosal columnar epithelial cells and replicate within
a parasitophorous vacuole termed an inclusion. A biphasic developmental cycle (3) is
manifested during infections in which a nonmetabolic elementary body (EB) invades a
host cell and subsequently transitions to the replicative, yet noninfectious, reticulate
body (RB). The cycle is completed by asynchronous differentiation of RBs back into EBs
and subsequent extrusion of the inclusion or lysis of the host cell (4). Historically
challenged by a lack of genetic tools, the molecular mechanisms governing these
processes are now coming into better focus due to development of approaches to
transform Chlamydia (5, 6), ectopically express chlamydial genes (7–10), and create
random (11) or targeted (12, 13) mutations. These advances have culminated in the
ability to completely delete targeted chlamydial genes via fluorescence-reported allelic
exchange mutagenesis (FRAEM) (14).
As an obligate intracellular pathogen, invasion of new host cells represents the first
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essential step in initiating and perpetuating chlamydial infection. Given the importance
of this process, chlamydial entry into nonphagocytic epithelial cells involves multiple,
likely redundant pathways (15). Indeed, serovar- and species-specific differences in
attachment and entry requirements have been described (16), and interference with
any one pathway does not lead to complete inhibition of chlamydial invasion. Despite
complexities, key themes have emerged regarding chlamydial entry into epithelial cells.
First, chlamydial EBs are completely competent for invasion, since neither de novo
transcription nor translation are required for entry (17). This is consistent with data (18)
indicating the EBs are preloaded with proteins known to be necessary for orchestrating
the invasion process. Attachment in cell culture occurs through a two-step process
involving an initial, reversible electrostatic interaction between glycan moieties on the
EB and host cell heparan sulfate-containing glycosaminoglycans (19–23). Initial associ-
ation is followed by irreversible binding to the host cell surface through specific
receptors (24, 25). Following attachment, Chlamydia and host proteins converge to
create an infection synapse where assembled signaling platforms remodel host
cytoskeleton-associated factors to promote invasion (26). C. trachomatis-induced re-
modeling of the cytoskeleton is localized to points of chlamydial attachment and is
required for entry (27). Manipulation of host cell actin is a conserved requirement for
efficient chlamydial invasion (16, 26), as treatment of epithelial cells with cytochalasin
D (28) or jasplakinolide (26, 29) or expression of dominant-negative Rac1 (30, 31)
interferes with entry of C. trachomatis. Subsequent to entry, nascent inclusions remain
segregated from the endosomal-lysosomal compartment, a process that requires ma-
nipulation of host Rab GTPases and vesicle fusion machinery (32). Inclusions traffic to
the microtubule-organizing center, where they remain anchored and intercept lipids
and other resources required for further development (33).
Similar to other Gram-negative pathogens (34), C. trachomatis employs a type III
secretion system (T3SS) to accomplish secretion and translocation of anti-host effector
proteins into an associated host cell (35). Prior to invasion, EBs possess secretion-
capable T3SSs (36, 37) and contain pools of previously synthesized effectors (18)
capable of being secreted during the invasion process. The most thoroughly charac-
terized effector is the translocated actin recruiting protein (TarP), which directly nucle-
ates and polymerizes actin (29, 38–43). The central repeat units of TarP also serve as
scaffolding for host guanine nucleotide exchange factors which regulate signaling
pertaining to actin dynamics and recruitment (43). Microinjection of host cells with
TarP-specific antibodies reduces the efficiency of chlamydial entry (41). Efficient trans-
location of TarP requires SycE-like chaperone-1(Slc1) (44), and Slc1 binds additional
effector proteins originally designated CT694, CT695, and CT875 (45, 46). CT875, now
designated translocated early phosphoprotein (TepP), is secreted during invasion and
recruits host CrkL and phosphatidylinositol 3-kinase (47) to entry sites, yet chlamydial
null mutants lacking TepP were not defective for entry (46). Previously referred to using
nomenclature first established in C. trachomatis serovar D (48), CT694, CT695, and
CT696 correspond to C. trachomatis L2 proteins designated CTL0063, CTL0064, and
CTL0065, respectively. The proteins are highly conserved among trachomatis serotypes,
exhibiting 99% identity. Both C. trachomatis CT694/CTL0063 (49) and CT695/CTL0064
(9) are secreted during chlamydial entry and are capable of peripherally associating
with eukaryotic membranes (9, 50). Based on their described properties, we propose
the designation translocated membrane-associated effectors A (TmeA) and B (TmeB) for
CT694/CTL0063 and CT695/CTL0064, respectively.
TmeA binds human AHNAK (49), a ubiquitously expressed 700-kDa phosphoprotein
capable of localizing to the cytoplasm, nucleus, and plasma membrane of cells in
response to a variety of stimuli (51–56). Importantly, AHNAK is localized to the apical
membranes of polarized epithelial cells and contributes to maintenance of apical
cytoarchitecture (57). AHNAK has a tripartite structure consisting of a short 251-residue
amino-terminal (N-terminal) domain and a 1,002-residue carboxyl-terminal (C-terminal)
domain connected by a 4,300-residue central region comprised of 39 conserved central
repeat units (CRU) (58). C. trachomatis TmeA was found to be capable of binding either
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the CRUs or the C-terminal domain of AHNAK in a yeast two-hybrid screen (49). AHNAK
CRUs are predicted to form -propeller-like structures that confer scaffolding function
for interactions of AHNAK with other host proteins (59). CRUs contribute to membrane-
associated signaling events through direct interactions with protein kinase C-alpha
(PKC) and phospholipase C-gamma (PLC) (59–61). The C-terminal domain of AHNAK
exerts roles in actin dynamics by serving as a scaffold for assembly of cytoskeletal
elements and membrane-associated signaling (58, 60, 62–65). AHNAK functions directly
in actin dynamics via C-terminal-dependent bundling of filamentous actin (64) and
indirectly through interaction with the tetrameric annexin A2-S100A10 (A2t) complex
(66, 67). The AHNAK-A2t complex has been implicated in maintaining the cortical actin
cytoskeleton (57) and serving as scaffolding for membrane repair (68).
Based on previous data, we hypothesized that TmeA (and possibly TmeB) is required
for chlamydial invasion. Given the newly acquired tractability in chlamydial genetics,
this hypothesis is now directly testable. Indeed, we recently reported the successful
deletion of both tmeA and tmeB in C. trachomatis L2 using FRAEM (14). Although no
developmental phenotype was detected for tmeB chlamydiae, the tmeA deletion
resulted in decreased infectivity in a murine model and manifested as a reproducible
defect at the level of host cell invasion. Interestingly, AHNAK colocalizes with invading
chlamydiae, and the TmeA interaction with AHNAK disrupts AHNAK-dependent actin
bundling activity. However, our data are consistent with an AHNAK-independent role of
TmeA in C. trachomatis invasion, reinforcing a working model where TmeA represents
a multifunctional effector.
RESULTS
Phenotypic characterization of C. trachomatis tmeA strain. Recent advances in
the genetic manipulation of chlamydiae have enabled more definitive functional
characterization of chlamydial gene products. We recently reported the FRAEM-
mediated construction of C. trachomatis L2 strains lacking coding sequences for
CTL0063 (TmeA), CTL0064 (TmeB), and the downstream, but independently expressed,
CTL0065. Both TmeA and TmeB are type III secreted effectors (TS3Es), whereas secretion
of CTL0065 has not been demonstrated. We began our phenotypic assessment by
testing whether developmental defects were manifested in null strains (Fig. 1). The
ctl0065 strain was included for comparison. HeLa cells were infected with equal
inclusion-forming units (IFUs) of C. trachomatis wild-type (WT) or mutant strains, and
inclusions were visualized at 24 h postinfection (hpi) by staining for chlamydiae and
the inclusion membrane protein IncG. Consistent levels of infection were confirmed by
enumeration of inclusions (data not shown). We did not detect any overt qualitative
differences in inclusion morphology (Fig. 1A), and measurement of inclusion area did
not reveal differences in the ability of strains to establish mature-sized inclusions (Fig.
1B). We next tested the ability of strains to produce progeny EBs by equally infecting
HeLa cells, harvesting cultures at times corresponding to early-cycle (1 and 6 h),
midcycle (12 h), and late-cycle (24 and 48 h) development, and enumerating subse-
quent second-passage IFUs (Fig. 1C). Under these conditions, progeny counts were
similar at all tested time points when comparing C. trachomatis WT and tmeA and tmeB
strains. In contrast, production of progeny chlamydiae was attenuated for ctl0065
chlamydiae, with the 48-h burst size being reduced ca. 10-fold. Finally, we chose to
enumerate chlamydial genomes during serial passage of cultures as a mechanism to
detect more subtle differences in infectivity. HeLa cultures were initially infected with
equal IFUs, and material was subsequently passaged onto new monolayers every 24 h.
Samples were removed and processed for quantitative PCR (qPCR)-based quantitation
of chlamydial genomes at every passage (Fig. 1D). Growth of the tmeB strain did not
differ significantly from that of the WT, whereas levels of genomes from the tmeA strain
steadily decreased and were 34.3% (11.1%) of that of the WT by the fourth sampling.
As expected, infectivity of the ctl0065 strain was also reduced, yielding 3.4% (1.7%) as
many progeny as the WT by the final time point. Linear regression analysis revealed a
statistically significant, progressive decrease in chlamydial genomes for tmeA and
TmeA during Chlamydial Infection Infection and Immunity
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ctl0065 but not tmeB chlamydiae. These data indicate that disruption of either tmeA or
ctl0065 negatively impacts the ability of chlamydiae to sustain infection. The distinctive
phenotype exhibited by the ctl0065 strain confirms our earlier observations that the
mutations in tmeA and tmeB did not affect CTL0065 expression (14). Since there is
currently no evidence that CTL0065 is a T3SE, we proceeded with characterization of
only the tmeA and tmeB strains.
We normalized infections for numbers of bacteria to more directly test for defects in
development. Genome content was deduced for WT, tmeA, and tmeB strains of C.
trachomatis via qPCR, and duplicate sets of HeLa monolayers were infected by rocking
cultures for 1 h at 37°C with inocula containing equal numbers of genomes. IFU content
was determined in primary cultures (Fig. 2A) and in parallel cultures harvested for
progeny counts (Fig. 2B). Under these infection conditions, the tmeA, but not tmeB,
strain of C. trachomatis yielded significantly fewer inclusions than the WT. The C.
trachomatis tmeA strain direct IFU counts in primary cultures were reduced ca. 52%
while progeny counts were ca. 43% of WT levels. Similar results were obtained when
infections were normalized by particle counts (data not shown). Since no phenotype
was detected with the tmeB strain, we conclude from these data that only TmeA is
required for efficient infection of HeLa cells.
Lack of TmeA results in decreased infectivity and invasion. We have previously
demonstrated that the bla-gfp marker inserted in place of tmeA exerts a polar effect on
TmeB expression (14). Although our tmeB-deficient strain showed no decrease in
infectivity, we could not rule out the possibility that infectivity defects manifested by
FIG 1 Deletion of tmeA impacts infectivity independent of growth rate. HeLa cells were infected with equal IFUs of WT, tmeA, tmeB, or ctl0065
strains of C. trachomatis L2. Cultures were methanol fixed at 24 hpi and stained to visualize chlamydial inclusions via indirect immunofluorescence.
(A) Inclusions were visualized by staining with Hsp60 (red) and IncG (green). Bar, 2 m. (B) Areas of 50 representative inclusions were measured
and plotted individually and with respective means and standard deviations shown. (C) Cultures were harvested over time (1, 6, 24, and 48 h)
for enumeration of progeny chlamydiae. Two-way ANOVA was performed to establish statistical significance (*, P  0.0001). (D) Alternatively,
cultures were serially passaged onto fresh HeLa monolayers every 24 h and genome content was quantitated via qPCR at each passage. Direct
and progeny inclusion counts (B and C) were derived from triplicate cultures, and data are reported as means  SD. In panel D, the 16S copy
number for each 24-h passage number is presented relative to the wild type as means SD (n 3). Linear regression analysis indicates significant
differences in slope over time (*, P  0.0059; **, P  0.0002).
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our tmeA strain were due to lack of both effectors. Complementation studies therefore
were performed to address this question. We cloned tmeA and 292 nucleotides (nt) of
upstream DNA into our expression vector, pCompAII, and mobilized this plasmid into
the tmeA strain. TmeA expression was first confirmed by immunoblotting of EBs (Fig.
3A) or whole-culture material harvested 12 or 24 hpi (Fig. 3B). TmeA was detected in
levels comparable to those of the WT in both EBs and 24-h whole-culture material. As
expected, TmeB was not detected in either the tmeA or tmeAptemA strains. Having
established comparable expression of ectopic tmeA, HeLa monolayers were infected
with equal particles of WT, tmeA, and tmeAptmeA C. trachomatis strains, and inclu-
sions were enumerated 24 hpi (Fig. 3C). Inclusion abundance was reduced in tmeA, but
not tmeAptmeA, cultures compared to that of the WT. Therefore, we conclude that
the infection defect is due solely to loss of tmeA. We next extended this analysis to the
murine infection model to gauge the requirement of TmeA during in vivo infection (Fig.
3D). Mice were infected with equal IFUs of WT, tmeA, and tmeAptmeA C. trachomatis
strains, and shed IFUs were enumerated over time. Although infectious loads were
similar at days 3 and 7, the tmeA strain was attenuated compared to the WT, since tmeA
strain-infected mice resolved infections by day 11. In contrast, mice remained infected
with the complemented strain, and IFU counts were similar to those of the WT until day
19. Hence, TmeA is required for in vivo virulence and the tmeAmutation can be partially
complemented with tmeA alone.
We next sought to establish the step at which chlamydial development was
impaired. Intracellular tmeA strain organisms develop similarly to WT organisms
FIG 2 Infections using equivalent numbers of bacteria reveal an infectivity defect for C. trachomatis
lacking TmeA. Duplicate sets of HeLa cultures were infected in triplicate with equal numbers (as
determined by genome copy number) of C. trachomatis WT, tmeA, or tmeB strain to achieve an
approximate MOI of 0.1. At 24 h postinfection, one set of cultures was methanol fixed and stained for
chlamydiae (A), while the second was processed for enumeration of progeny EBs by passage onto fresh
HeLa monolayers (B). All inclusions were enumerated by fluorescence staining of chlamydiae in fixed
samples, and data for direct and progeny counts are represented as means  standard deviations from
triplicate samples. Student’s t test with Welch’s correction was used to address significance (*, P  0.008;
**, P  0.009).
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(Fig. 1C), and we did not detect a difference in tmeA strain attachment efficiency (data
not shown). We therefore considered the possibility that invasion efficiency was altered
in our tmeA strain. HeLa monolayers were infected with the WT or tmeA strain at 4°C to
allow attachment, shifted to 37°C to promote entry, and processed to differentiate
intracellular and extracellular bacteria, as described previously (27), via indirect immu-
nofluorescence (Fig. 4). We also included cultures supplemented with cytochalasin D as
FIG 3 Complementation with TmeA restores infectivity to WT levels. Material from equivalent particles of purified WT, tmeA, or
complemented tmeA (tmeAptmeA) EBs (A) or cultures infected at an MOI of 1 were probed in immunoblots for TmeA and TmeB (B).
Chlamydial Hsp60 and HeLa cell actin were examined as loading controls. All proteins were visualized by chemiluminescent
development. (C) HeLa cells were infected with equal numbers of WT, tmeA, or tmeAptmeA EBs and processed for enumeration of
IFUs at 24 hpi. Data are represented as means  standard deviations from triplicate samples. Student’s t test with Welch’s correction
was used to address significance (*, P  0.008). (D) Groups of 5 female C3H/HeJ mice were infected intravaginally with equal input
IFUs, and shed IFUs were enumerated at days 3, 7, 11, 15, 19, and 23 postinfection. Two-way ANOVA was performed to establish
statistical significance (*, P  0.0001).
FIG 4 TmeA contributes to infection during the invasion process. HeLa monolayers were infected for 1
h at 4°C with the WT or tmeA strain of C. trachomatis L2 at an MOI of 10. Infections were carried out in
the presence of vehicle control or with cytochalasin D. Cultures were shifted to 37°C for 30 min and then
paraformaldehyde fixed. External EBs were specifically labeled with MOMP-specific antibodies, and
internalized bacteria were labeled in subsequently permeabilized cultures using Chlamydia-specific
antibodies. Data are represented as mean values for percentage of internalized chlamydiae and are
shown with standard deviations. Statistical significance was computed using Student’s t test with Welch’s
correction (*, P  0.0134; **, P  0.0131; ***, P  0.0028).
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positive controls for inhibition of invasion. As expected, cytochalasin D treatment
reduced invasion of both strains. In addition, the level of intracellular tmeA bacteria was
reduced ca. 37% relative to the WT. These data implicate invasion as the developmental
step that is impaired in the absence of TmeA. We could not assess invasion of the
complementation strain, since the assay requires differential staining and the
tmeAptmeA strain is already green and red.
Endogenous AHNAK is recruited transiently to nascent inclusions indepen-
dently of TmeA. We have previously identified an interaction of TmeA with human
AHNAK (49) and wondered if disruption of this interaction could explain the invasion
defect manifested by the C. trachomatis tmeA strain. We began our investigation of
AHNAK by infecting HeLa cells with WT C. trachomatis and visualizing endogenous
AHNAK in cultures fixed and stained 1 or 8 hpi (Fig. 5). Chlamydiae were stained with
major outer membrane protein (MOMP)-specific antibodies, and we detected clear
colocalization of Chlamydia and AHNAK at 1 hpi when focusing on the apical surface of
HeLa cells (Fig. 5A). No colocalizing AHNAK signal was detected in cultures fixed 8 hpi
(Fig. 5B). To narrow the duration of AHNAK colocalization with WT chlamydiae, we
enumerated AHNAK-positive EBs in cultures fixed at 0.5, 1, 2, and 4 hpi (Fig. 5C).
Colocalization was maximal at 30 min, with punctate AHNAK signal adjacent to 48.3%
FIG 5 Endogenous AHNAK is transiently recruited to the site of chlamydial entry independently of TmeA. HeLa cells were infected at an MOI of 20 with the
C. trachomatis WT or tmeA strain at 4°C. Cultures were shifted to 37°C for the indicated times and subsequently fixed with paraformaldehyde and processed
for indirect immunofluorescence analyses. Merged-color epifluorescence micrographs are shown where chlamydiae were detected with anti-MOMP and AHNAK
was detected with specific antibodies. Individual channels are depicted for insets and demonstrate positions of EBs and AHNAK. Scale bars, 5 m. (A) AHNAK
(green) position relative to WT C. trachomatis (red) after 30 min at 37°C. (B) AHNAK (green) position relative to WT C. trachomatis (red) after 8 h at 37°C. (C)
AHNAK colocalization with EBs was directly quantitated in cultures fixed 30, 60, 120, and 240 min after temperature shift. Representative data are presented
as the mean values (with standard deviations) for percentages of EBs associated with AHNAK-specific signal. (D) AHNAK (red) position relative to tmeA strain
of C. trachomatis (green) after 30 min at 37°C.
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(3.5%) of EBs. AHNAK-EB colocalization decreased steadily, and 89.7% (1.0%) of EBs
were not associated with detectible AHNAK signal at 4 hpi. Finally, we tested whether
EB-AHNAK colocalization was required TmeA by similarly examining tmeA strain-
infected cultures at 0.5 hpi (Fig. 5D). As with WT C. trachomatis, AHNAK staining was
readily detectible in association with tmeA EBs. In aggregate, these data indicate that
endogenous AHNAK is transiently recruited to the site of invading EBs, yet this process
does not require TmeA.
TmeA interacts with AHNAK during invasion. TmeA interacts with the C-terminal
domain of AHNAK, and this 1,000-residue portion of AHNAK has been successfully
expressed for functional studies (64, 65). We further examined AHNAK recruitment by
invading EBs by expressing the C-terminal domain of AHNAK fused to mCherry (Fig. 6A).
HeLa cells expressing mCherry or mCherry AHNAK were infected with the WT or tmeA
strain and fixed 30 min after infection. Immunofluorescence analysis indicated a clear
colocalization of EBs with mCherry-AHNAK but not mCherry. Interestingly, no colocal-
ization was detected when cells were infected with the tmeA strain, raising the
possibility that TmeA and AHANK do indeed interact during entry. Proximity labeling
(69) has recently been applied to study the interaction of chlamydial effectors with host
factors (70). We were unable to create TmeA- and BirA-containing chimeras for expres-
sion in Chlamydia, since N-terminal fusions would block T3S and a C-terminal fusion
was inactive (data not shown). Therefore, we performed the reciprocal experiment by
infecting HeLa cells expressing a chimeric protein containing the C-terminal domain of
AHNAK fused to BirA. Perforin-2 associates with the nascent chlamydial inclusion (71)
and was similarly fused to BirA as a negative control. Cultures were preinduced with
biotin for 15 h prior to infection, and immunoblot analysis of whole-culture material
from parallel cultures confirmed that fusion proteins contained active BirA (Fig. 6B).
HeLa cells were infected in the presence of biotin for 5 h with WT Chlamydia and then
harvested, and biotinylated proteins were purified via immunoprecipitation (Fig. 6C).
Samples of the cleared lysate and immunoprecipitates were probed with TmeA-specific
antibodies to test for protein proximity. Blots were probed for nonsecreted (Hsp60) or
FIG 6 Association of AHNAK and TmeA during chlamydial invasion. (A) HeLa cells were nucleofected with pmCherry or pmCherry-Ahnak. At 24 h cells were
infected at 4°C with C. trachomatis L2 WT or tmeA strain at an MOI of 20. Cultures were shifted to 37°C for 30 min and subsequently were fixed with
paraformaldehyde and processed for direct and indirect immunofluorescence. Chlamydia organisms were detected using anti-MOMP (green). mCherry or
mCherry-Ahnak (red) is shown in the mCherry channel. Scale bar, 5 m. (B) HeLa cells or cells expressing P2-BirA or AHNAK-BirA were cultivated in the presence
of biotin for 15 h, and whole-culture material was resolved via SDS-PAGE. Material was probed with NeutrAvidin-HRP to visualize biotin- or actin-specific
antibodies as a loading control. Positions of molecular size markers are indicated. (C) Biotinylated proteins were immunoprecipitated (IP) from cleared lysates
of cultures infected for 5 h and expressing P2-BirA or AHNAK-BirA. Material from cleared lysates (lysate) or immunoprecipitates was probed with Hsp60-, TarP-,
TmeA-, or annexin A2-specific antibodies in immunoblots and visualized via chemiluminescent detection.
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December 2017 Volume 85 Issue 12 e00640-17 iai.asm.org 8
secreted (TarP) chlamydial proteins as negative controls. AHNAK interacts with annexin
A2 (57, 66), and this protein served as a positive control. Signals in lysate material
indicated the abundant presence of all proteins. As expected, TmeA was biotinylated by
AHNAK-BirA but not P2-BirA, whereas no evidence of TarP or Hsp60 biotinylation was
observed. Annexin A2 was detected in immunoprecipitation material from both P2- and
AHNAK-BirA. Collectively, these data indicate an interaction of TmeA and AHNAK during
early events in chlamydial infection.
C. trachomatis TmeA interferes with AHNAK-dependent actin bundling. The
carboxyl-terminal domain of AHNAK binds both G- and F-actin (65) and mediates
bundling of F-actin (64). We asked whether TmeA is capable of altering AHNAK-actin
interactions and began by testing whether TmeA affected AHNAK-dependent actin
bundling activity in an in vitro sedimentation assay. Filamentous (F)--actin from rabbit
skeletal muscle was subjected to differential centrifugation in the presence of full-
length, glutathione S-transferase (GST)-tagged TmeA and/or GST-tagged AHNAK
C-terminal domain corresponding to the terminal 1,000 residues. The resulting pellet
and supernatant fractions were resolved by SDS-PAGE, and actin was visualized by
Coomassie blue staining while GST-TmeA and GST-AHNAK were detected via immu-
noblotting (Fig. 7A). As expected, actin was detected predominately in the supernatant
FIG 7 TmeA inhibits AHNAK-dependent F-actin bundling activity in vitro. Rabbit skeletal muscle F-actin was subjected to low-speed (12,000 
g) differential centrifugation in the presence or absence of GST-tagged or control proteins. All recombinant proteins were mixed at 1:1 molar
ratios. Samples subsequently were separated into supernatant (S) and pellet (P) fractions. Equal volumes of material were resolved by SDS-PAGE,
and actin was visualized by Coomassie blue staining. (A) GST-AHNAK and GST-TmeA were detected by immunoblotting with AHNAK-specific or
TmeA-specific antibodies and visualized via chemiluminescence after probing with secondary antibodies coupled to HRP. Numerical values
represent the relative percentage of actin in respective fractions. (B) Actin, -actinin, and GST-TmeA were visualized via Coomassie blue staining.
(C) F-actin alone or in combination with GST-694 and/or GST-AHNAK in a 1:1 or 1:1:1 molar ratio was processed for visualization by transmission
electron microscopy. Samples were visualized at 10,500 and 64,000 magnification, and representative images are shown. Scale bar, 1 m.
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fraction when GST-AHNAK was not present (21.3% in pellet). Consistent with its role in
actin bundling, inclusion of GST-AHNAK resulted in a shift of actin into the pellet
(60.6%) fraction. GST-TmeA alone did not affect actin partitioning. However, inclusion
of GST-TmeA with GST-AHNAK resulted in actin partitioning similar to that of the
actin-alone treatment (24.8% in the pellet). Neither bovine serum albumin (BSA) nor
GST affected actin partitioning (data not shown). The actin bundling protein -actinin
was used as a positive control (Fig. 7B). As expected, actin distribution was most
abundant in pellet fractions in the presence of -actinin. Moreover, addition of GST-
TmeA did not affect the -actinin-mediated shift in actin partitioning. In aggregate,
these data indicate that TmeA is able to disrupt AHNAK-dependent actin bundling.
Furthermore, GST-AHNAK and -actinin were detected in pellet fractions. This is
consistent with observations that proteins which bind F-actin will copellet with the
bundled actin. Although GST-TmeA was detectable in pellet fractions, this did not
require the presence of actin, suggesting that the localization is not indicative of an
interaction between actin and GST-TmeA.
Analysis of material via transmission electron microscopy was used to confirm the
impact of GST-tagged proteins on actin structure (Fig. 7C). Filamentous -actin was
incubated with GST-TmeA, GST-AHNAK, or both proteins at a 1:1 molar ratio and
negatively stained. Compared with F-actin only and consistent with previous reports
(64), web-like bundles of actin were detected in the sample of F-actin incubated with
GST-AHNAK. While GST-TmeA alone did not seem to have an impact on gross actin
structure, inclusion of GST-TmeA with GST-AHNAK resulted in actin fibers, similar to the
negative controls. These data are consistent with our conclusion that C. trachomatis
TmeA is capable of interfering with the actin bundling activity of AHNAK.
Evidence for AHNAK-independent functions for TmeA. Knockdown of AHNAK via
short interfering RNA (siRNA) treatment of epithelial cells has been reported (57), yet
depletion of HeLa cell AHNAK is neither efficient nor complete (data not shown). Lee et
al. (60) generated and characterized an ahnak knockout (KO) murine line that has
proven efficacious in studying the roles of AHNAK in eukaryotic cell biology. We
therefore leveraged these mice by isolating murine embryonic fibroblasts (MEFs) from
embryos derived from heterozygous (HET) matings. PCR and immunoblot analyses
were employed to confirm MEF genotype, and WT, HET, and KO cells appeared to grow
equivalently in tissue culture (see Fig. S1 in the supplemental material). Passage-
matched MEFs derived from littermates then were used to compare growth and
development of C. trachomatis in the presence or absence of AHNAK (Fig. 8). Parallel WT
and KO MEF monolayers were grown to equal confluence and infected at 37°C with C.
trachomatis L2 at a multiplicity of infection (MOI) of 1. When cultures were fixed 24 hpi
and processed to quantitate direct IFU counts, we did not detect any difference in the
FIG 8 Analysis of C. trachomatis infection in AHNAK-deficient MEFs. (A) WT or ahnak homozygous knockout (KO) MEFs were infected at an MOI of 1 with WT
C. trachomatis. Cultures were fixed at 24 h postinfection for direct IFU counts. (B) WT KO MEFs were infected for 1 h at 4°C with C. trachomatis L2 at an MOI
of 10. Infections were carried out in the presence of vehicle control or cytochalasin D (CytoD). Cultures were shifted to 37°C for 30 min and then
paraformaldehyde fixed. External EBs were specifically labeled with MOMP-specific antibodies, and internalized bacteria were labeled in subsequently
permeabilized cultures using Chlamydia-specific antibodies (**, P 0.0001). (C) KO MEFs were infected with equal particles of WT or tmeAmutant C. trachomatis
at an MOI of 0.5. Cultures were processed for direct enumeration of inclusions at 24 hpi (*, P 0.003). All data are represented as means with standard deviations
calculated from triplicate cultures. Student’s t test with Welch’s correction was employed to assess statistical significance.
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ability of Chlamydia to establish infection in KO cells (Fig. 8A). With no difference
distinguishable in infectivity, we progressed to test whether invasion defects where
apparent in the absence of AHNAK (Fig. 8B). Parallel cultures of MEF monolayers were
infected with C. trachomatis serovar L2 at an MOI of 10 at 4°C and processed to examine
invasion. Addition of cytochalasin D was used as a positive control for reduction of
chlamydial invasion. A proportion of 67.9% 9.1% of C. trachomatis organisms invaded
WT MEFs, and this was significantly reduced by the presence of cytochalasin D (5.6% 
2.3%). Similarly, chlamydial invasion of untreated KO MEFs was 60.8%  8.8%, and this
was reduced to 11.2% 5.1% in the presence of cytochalasin D. Collectively, these data
indicate that AHNAK-dependent functions are not required to support chlamydial
invasion. However, the data would be consistent with a situation where TmeA nega-
tively impacts AHNAK to promote invasion, perhaps via disruption of the AHNAK-
dependent actin bundling activity. Therefore, we infected KO MEFs with WT and tmeA
strains to test whether the tmeA strain-specific infectivity defect was manifested in
these cells (Fig. 8C). Similar to HeLa cell infections, we observed a ca. 45% decrease in
tmeA strain IFUs compared to those of the WT. These data indicate that the infectivity
defect manifested by the lack of TmeA occurs independently of AHNAK and is consis-
tent with alternative TmeA-mediated activities.
DISCUSSION
Increased efficacy of genetic manipulation in C. trachomatis is steadily progressing.
Random, chemical-induced mutagenesis coupled with tilling (12) was originally em-
ployed to inactivate chlamydial genes. Whole-genome sequencing has now provided a
useful platform for forward genetic approaches (11). Reproducible transformation of
Chlamydia with a stably maintained plasmid represents perhaps the most significant
breakthrough to date (5). This ability enabled targeted gene disruption via insertion
mutagenesis using a group II intron (13). We developed FRAEM for complete gene
deletion, since the most definitive functional studies require complete deletion of
target genes. This approach was used to successfully delete coding sequences for
CTL0063, CTL0064, and CTL0065 (14). In the present study, we applied a reverse genetic
approach to examine the impact of these mutations on chlamydial infectivity. Our data
indicate that TmeA (CTL0063) is essential for efficient infection in both animal and
tissue culture models.
Proteins secreted via the T3S mechanism directly impact virulence in numerous
Gram-negative pathogens (72). TmeA (CTL0063) and TmeB (CTL0064) represent estab-
lished effectors of the chlamydial T3SS (9, 46, 49, 73). Both effectors appear to be
Chlamydia-specific, yet tmeA is unique to C. trachomatis genomes and belongs to a
family of cytoskeleton-interactive effectors due to the presence of an N-terminally
positioned membrane localization domain (50). Both chlamydial effectors have been
implicated in invasion due to deployment during chlamydial entry. Although below
detection in the host cytosol after 4 h, TmeA-specific signal is detectable via immuno-
blotting throughout development, even at times prior to de novo synthesis (49). In
contrast, TmeB is detectible via indirect immunofluorescence and clearly colocalizes
with inclusion membranes during late-cycle development (9). It was therefore initially
possible that tmeA- or tmeB-specific phenotypes could manifest at any point in chla-
mydial development. Indeed, we detected a reproducible negative impact on chlamyd-
ial infectivity in the absence of TmeA that correlated with a defect in invasion. This was
in contrast to the delayed development phenotype apparent in the ctl0065 strain. We
did not detect any overt developmental defect for tmeB chlamydiae. This does not rule
out a role in the invasion process due to several possibilities. For example, functional
redundancy among effectors could provide an explanation (see below). Since columnar
epithelial cells represent the in vivo replication niche for Chlamydia, it is also possible
that TmeB-mediated functions are not manifested in the HeLa cell infection model.
Finally, TmeB may function independently of processes required for physical entry of
EBs. For example, TepP represents another effector secreted during invasion. TepP
recruits Crk-II during entry, yet a tepP-deficient strain was not impaired for entry (46).
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Application of FRAEM results in replacement of targeted chromosomal coding
sequences with an antibiotic resistance gene for selection and GFP for detection. Our
immunoblot analysis confirmed that this insertion in tmeA has a polar effect on tmeB
expression. This was not surprising given that tmeA and tmeB are cotranscribed (9).
There is no evidence that the tmeA or tmeB mutation impacted expression of ctl0065.
Although encoded downstream, ctl0065 transcription occurs independently (9) and
wild-type levels of CTL0065 are detectable by immunoblotting in material from tmeA
and tmeB chlamydiae (14). Furthermore, the delayed development observed here for
the ctl0065mutant was distinct from tmeA and tmeB strain phenotypes. The polar effect
of the tmeA mutation on TmeB, however, necessitated complementation studies. We
mobilized tmeA and 292 nt of upstream DNA, containing the endogenous promoter
and transcription start site (74), into pComAII for complementation studies. Trans-
expressed TmeA was detected in both EBs and during the late cycle, indicating an
expression profile consistent with endogenous tmeA. TmeB was not detected in the
complemented strain, ruling out the possibility that TmeA expression is required for
TmeB stability. Complementation with tmeA restored WT levels of inclusion counts,
verifying that the developmental phenotype manifested in the mutant was due solely
to loss of tmeA. We were surprised that trans-expression of tmeA also complemented
the infectivity defect observed in mice. Shed EBs for the complemented strain were
roughly decreased compared to the level for the WT after day 15, indicating that
complementation was not entirely complete. These data suggest that loss of tmeB
manifests as a more modest defect for C. trachomatis L2 intravaginal infection of mice.
The decreased ability to produce inclusions by tmeA chlamydiae could result from
deficiencies in attachment, entry, or postentry survival. We did not detect reductions in
tmeA C. trachomatis attachment (data not shown), and the WT levels of development
observed during IFU-normalized infections make it unlikely that postentry survival is
reduced in the absence of TmeA. Importantly, we did observe a decrease in tmeA
invasion efficiency. This decrease was reproducible but modest in magnitude. One
possible explanation for this modest impact is that, similarly to Legionella pneumophila
(75), deletion of a single gene may not reveal overt phenotypes due to potential
redundancy in effector function. As noted above, Chlamydia deploy multiple known
effectors during the invasion process, and others are likely waiting to be identified. We
believe, however, that the most likely explanation is that Chlamydia employ multiple
invasion mechanisms to gain access to the interior of host cells. C. trachomatis invasion
remains incompletely characterized but involves initial electrostatic association with
target cells (16). This is followed by irreversible engagement of host receptors, such as
platelet-derived growth factor receptor (76), protein disulfide isomerase (77), integrin
1 (78), epidermal growth factor receptor (79), and EphA2 (80), which have been
implicated in C. trachomatis attachment and/or invasion. Numerous potential chlamyd-
ial adhesins have been implicated. For example, polymorphic outer membrane protein
D (81) and Ctad1 (78) are important for attachment of C. trachomatis. Although specific
host factor requirements can vary by chlamydial species, entry of attached EBs is largely
driven by recruitment and rearrangement of the actin-based cytoskeleton (16). As
recently outlined by Stallmann and Hegemann (78), the range of bacterial and host
factors that have been identified implicate multiple, redundant entry mechanisms.
Interestingly, interference with any one of these pathways results in only modest
decreases in invasion, similar in magnitude to that of the tmeA phenotype. Hence, we
conclude that TmeA plays an important role in T3S-mediated invasion but is not
absolutely essential for chlamydial entry due to redundant mechanisms. In contrast,
TmeA is absolutely required during intravaginal infections, since tmeA strain infections
of mice rapidly resolved. These data would be consistent with a more profound
invasion impact in the comparatively more complex in vivo scenario or additional
functions of TmeA.
TmeA is secreted during invasion, and we previously provided in vitro evidence for
an interaction of TmeA with host AHNAK (49). An involvement of AHNAK in bacterial
infection has precedent. During Salmonella enterica serovar Typhimurium infection,
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AHNAK is phosphorylated (82) and recruited to membrane ruffles (83) via a mechanism
dependent on the S. Typhimurium T3SS-1 effectors SopB and SopE/E2. Infection of WT
and KO MEFs revealed that AHNAK was essential for invasion of these cells by
Salmonella (83). Our data using the same ahnak KO MEFs indicate that AHNAK is not
required for chlamydial invasion or intracellular development. Furthermore, the
invasion defect detected during infection of HeLa cells with the tmeA strain was still
manifested in KO MEFs. These data argue against an active requirement of the
TmeA-AHNAK interaction for invasion.
However, our data do provide evidence for an interaction of TmeA and AHNAK
during early events. Although colocalization of endogenous AHNAK with invading EBs
did not require TmeA, recruitment of the C-terminal domain was not apparent for the
tmeA strain. Proximity labeling experiments were also consistent with a TmeA-AHNAK
interaction. AHNAK is a large, multidomain protein (58), and our data indicate that
other chlamydial or host factors could mediate AHNAK colocalization. It is unclear what
the role is for TmeA-independent AHNAK recruitment. Numerous functions have been
ascribed to AHNAK, including regulation of calcium channels, cellular architecture, and
membrane repair (reviewed in reference 84).
AHNAK is also involved in cytoskeleton dynamics, and this function appears to be
impacted by the TmeA-AHNAK interaction. The C terminus of AHNAK actively engages
the actin cytoskeleton and is capable of bundling actin fibers (64), and we employed a
standard in vitro actin bundling assay to demonstrate that TmeA interferes with this
bundling activity. Actin bundling proteins are defined by their ability to directly bind
and organize filamentous actin. While roles are diverse, actin bundling is important in
assembly of filopodia that are exploited by multiple bacterial pathogens to gain entry
into epithelial cells (85). Although chlamydiae do not induce membrane ruffles, EB
attachment to host cells is accompanied by formation of a pedestal-like structure (86)
and surrounding microvillar hypertrophy (27) on the cellular surface. We did not detect
a deficiency in actin recruitment by the tmeA strain (data not shown), and it should be
noted that C. trachomatis TarP has actin bundling activity (87). Since AHNAK was not
essential for invasion, these observations raise the possibility that TmeA-mediated
disruption of AHNAK-containing actin bundles is instrumental in the overall cytoskeletal
reorganization orchestrated subsequent to entry. This function might not directly
impact chlamydial fitness. As noted above, it is formally possible that redundant entry
pathways could also mask any functional impact of this activity in the tissue culture
infection model.
In aggregate, we have leveraged a novel genetic approach that enables generation
of bona fide null mutations to reveal an active role of TmeA in chlamydial infection and
invasion. This activity is independent of the interaction with AHNAK and is consistent
with TmeA representing a multifunctional effector. Indeed, a multifunctional character
would be consistent with evidence indicating differing functional domains within TmeA
(50). Ongoing studies are aimed at elucidating the molecular mechanisms governing
the role of TmeA in invasion and understanding how TmeA-dependent manipulation of
AHNAK function contributes to chlamydial infection.
MATERIALS AND METHODS
Cell cultures and organisms. C. trachomatis was routinely cultivated in HeLa 229 epithelial cell
monolayers (ATCC CCL-1.2), and chlamydial transformations were accomplished using McCoy cell
monolayers (CRL-1696; ATCC) as described previously (88). All cultures were maintained at 37°C in an
atmosphere of 5% CO2 and 95% humidified air in RPMI 1640 containing 2 mM L-glutamine (Life
Technologies) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (HIFBS; Sigma). All
infection studies employed HeLa cultures below passage 20 from the original stock. Murine embryonic
fibroblasts (MEFs) were derived from ahnak-deficient mice according to University of Kentucky IACUC-
approved protocols essentially as described previously (60). Fibroblasts were isolated at day 13.5 from
heterozygous ahnak knockout (KO) females that were bred to heterozygous ahnak KO males. Individual
MEF isolates derived from littermates were used for experiments. Each isolated culture was evaluated for
AHNAK production after a single passage by PCR and immunoblot analysis of isolated genomic DNA or
whole-cell protein, respectively. PCR-based genotyping was accomplished using an antisense primer
(5=-CCTCAGGAGCAGATGTCTTC-3=) paired with a separate sense primer (5=-CTGGATGGCCAGATTCC
AGAG-3= or 5=-CAGCTCATTCCTCCCACTCAT-3=) to discriminate between homozygous full-length (WT),
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heterozygous ahnak KO (HET), or homozygous KO alleles. Whole-culture proteins isolated from respec-
tive MEF isolates were probed with AHNAK-specific (49) or -actin-specific (Sigma) antibodies to evaluate
AHNAK levels via immunoblotting. MEFs were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) containing 4.5 g/liter (25 mM) D-glucose, 4 mM L-glutamine, and 110 mg/liter (1 mM) sodium
pyruvate (Life Technologies) and supplemented with 10% (vol/vol) HIFBS (Sigma) and 1% (vol/vol) 100
MEM nonessential amino acids solution (Life Technologies). All infection experiments were performed
using MEFs from passages 2 to 6.
These studies employed C. trachomatis serovar L2 (LGV 434) and previously described strains
harboring complete deletion of ctl0063, ctl0064, or ctl0065 (14). A complementation strain was generated
by first mobilizing tmeA with its endogenous promoter into pComA II (14) using engineered primers
(694pro@NmPgfp F, 5=-CGGTTCCTGGCCTTTTGCTGGGTACGGAAATACTATCTCCAGCTCAAAGC-3=, and
694@NmPgfp R, 5=-GCCCCGCCCTGCCACTCATCGGGACCGAACACCGTATACCTTCT-3=). The plasmid ptmeA
was transformed into Chlamydia, and clonal strains were isolated exactly as described previously (88). All
EBs were purified from HeLa cells by centrifugation through MD-76R (Mallinckrodt Pharmaceuticals)
density gradients (DG-purified) as previously described (89) and were used as the infection source for all
experiments. Escherichia coli NEB-10 (New England BioLabs) was utilized for routine cloning procedures,
while E. coli BL21-Al (Invitrogen) was used for production of GST and His-tagged proteins. E. coli was
routinely grown at 37°C in Luria-Bertani (Amresco) broth or LB agar plates supplemented with 50 g/ml
carbenicillin (Teknova) or 100 g/ml spectinomycin (Alfa Aesar) as appropriate.
Chlamydia infectivity and immunolocalization. Infection of cell monolayers with C. trachomatis
was carried out for the indicated time points at 37°C as previously described (89, 90) or as otherwise
indicated. Inocula for respective strains were normalized by either direct inclusion-forming units (IFUs) or
genome content. Chlamydial genomes were quantitated via qPCR of the 16S rRNA region as described
previously (14). Direct IFUs were assessed by processing cultures for indirect immunofluorescence and
visualization of chlamydiae with Hsp60-specific antibodies (Santa Cruz) after 24 h of infection. Enumer-
ation of progeny IFUs was accomplished via harvesting infected monolayers at the indicated times
postinfection in cold Hanks’ balanced salt solution (HBSS) (Life Technologies), passage of serial dilutions
onto fresh HeLa monolayers, and detection of inclusions via indirect immunofluorescence with Hsp60-
specific antibodies as described previously (91). Where indicated, relative inclusion areas were computed
from images acquired utilizing using a Zeiss epifluorescence microscope equipped with a 100 PlanApo
objective and AxioCam MRM camera. Images were imported into ImageJ, and areas were computed for
50 inclusions using the area measurement function. All IFU counts were assessed from triplicate cultures
plated in triplicate.
For immunolocalization studies, HeLa or MEF cells were cultivated on 12-mm glass coverslips. For
studies involving mCherry-tagged AHNAK, HeLa cells were transfected with pmCherry-AHNAK or vector
only using AMAXA (Lonza, Corp) nucleofection. Cells were infected with C. trachomatis at the indicated
MOIs. Samples were prepared for indirect immunofluorescence by fixation at the indicated time points
with 4% (wt/vol) paraformaldehyde (PFA; EM Science). Permeabilization was accomplished using 0.5%
Triton X-100 (Sigma-Aldrich) in phosphate-buffered saline (PBS) containing 3% (wt/vol) BSA (Sigma) for
20 min at room temperature. Fixed samples were blocked at room temperature for 1 h in 5% BSA in PBS
supplemented with 0.05% (vol/vol) Tween 20. Endogenous AHNAK was detected with anti-AHNAK
monoclonal antibody (Santa Cruz) and chlamydiae with anti-MOMP polyclonal (49) or anti-HSP60 (Santa
Cruz). Where indicated, IncG-specific antibodies (92) were used to define the inclusion periphery. Proteins
were subsequently visualized with secondary antibodies conjugated to Alexa Fluor 488 or 594 (Invitro-
gen). For epifluorescence microscopy, images were acquired using a 100 oil-immersion objective on a
Zeiss AX10 upright light microscope (Carl Zeiss Foundation, Oberkochen, Germany) with Zeiss AxioVision
software (Carl Zeiss Foundation). All images were processed equivalently using Adobe Photoshop 6.0
(Adobe Systems).
Murine infection studies. Groups of 5 female C3H/HeJ mice (Jackson Laboratory), 6 to 8 weeks old,
were intravaginally infected essentially as described previously (93). Mice were pretreated with 2.5 mg
medroxyprogesterone 5 days prior to infection. Mice were infected with 5  105 IFU of each chlamydial
strain, and shedding was monitored beginning on day 3 and then every 4 days until 2 consecutive time
points failed to yield EBs for the mutant strain. Recovered IFUs were enumerated on fresh HeLa cells as
described above. All manipulations were reviewed and approved by the University of Kentucky Institu-
tional Animal Care and Use Committee.
Invasion studies. The ability of chlamydiae to invade HeLa or MEF cells was conducted as described
previously (27), with modifications. Infections were carried out when cells reached ca. 70% confluence.
Where appropriate, cells were pretreated for 30 min with 2.5 g/ml cytochalasin D (Sigma). Plates were
cooled to 4°C for 10 min prior to inoculation and then infected with respective C. trachomatis strains at
an MOI of 10 in cold HBSS (containing dimethyl sulfoxide [DMSO] or cytochalasin D where appropriate)
for 1 h at 4°C to allow EBs to attach but not enter cells. Inoculate was replaced with 37°C medium
(containing drugs as appropriate) and maintained for 30 min. After thorough washes, cells were fixed on
ice with 4% (wt/vol) PFA and blocked for 20 min with 3% BSA. For probing, primary antibodies were
diluted in 3% BSA (Sigma-Aldrich) in PBS. External EBs were probed with -MOMP (49) and visualized
with secondary antibody conjugated to Alexa Fluor 488 (Invitrogen). Samples then were permeabilized
with 0.5% Triton X-100, stained with -Chlamydia lipopolysaccharide (LPS) (Novus Biologicals), and
visualized with secondary antibodies conjugated to Alexa Fluor 594 (Invitrogen). Percentages of invaded
chlamydiae where computed by enumeration of internal and external chlamydiae for a minimum of 100
bacteria in 10 fields of view. Percent EB internalization was calculated via the formula (total EBs 
external EBs)/total red EBs  100  percent invasion.
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DNA methods. The final 1,000 residues (4889 to 5890) representing the carboxyl-terminal domain of
the eukaryotic AHNAK gene were cloned into pmCherry (Clontech Laboratories, Inc., Mountain View, CA)
and pcDNA3.1 mycBioID (69) via amplification of the insert from HeLa cell cDNA isolated from the
ProQuest premade HeLa cDNA library (Invitrogen). DNA was amplified with Q5 high-fidelity (New
England BioLabs, Inc., Ipswich, MA) DNA polymerase according to the manufacturer’s protocols using
specified buffers and associated reagents. For pmCherry, a pair of custom oligonucleotide primers,
5=-CCGGAATTCCACGTCTGTTCGAAGGCC-3= and 5=-CCCGAATTCCTACTCTTTCTTTGTGGAAACTGACAGCTC
C-3= (Integrated DNA Technologies, Coralville, IA), were designed with specified engineered EcoRI
restriction sites. The primers 5=-AAAGCTAGCCTGGTATATGGATTTCGAAGGCCC-3= and 5=-AAACCGAATTC
CTCTTTCTTTGTGGAAACTGACAGCTCC-3=, containing an NheI or EcoRI restriction site, respectively, were
used for mobilization into pcDNA3.1 mycBioID. Cloning protocols were performed essentially as previ-
ously described (94). The full-length gene for Perforin-2 was also mobilized into pcDNA3.1 mycBioID via
amplification from RFP-P2 (95) using engineered primers (5=-AAAGCTAGCCTGGTATATGGCCAAAACC-3=
and 5=-AAACCGAATTCAGCTGGACTTGGATCCTC-3=) containing NheI and EcoRI restriction sites. Upon
sequencing verification, the constructs were prepped under endotoxin-free conditions with Zyppy
plasmid miniprep and maxiprep kits (Zymo Research) and QIAfilter plasmid and EndoFree plasmid maxi
kits (Qiagen).
Proximity labeling. Proximity labeling using the BioID approach was accomplished as described
previously (96), with modifications. HeLa cells alone or expressing P2-BirA or AHNAK-BirA were cultivated
in the presence of 50 M biotin for 15 h and then infected with WT Chlamydia at an MOI of 20 in the
presence of biotin. Cultures were maintained in 50 M biotin (Sigma) for an additional 5 h, washed with
HBSS, and disrupted in lysis buffer (50 mM Tris, pH 7.4, 500 mM NaCl, 0.2% SDS) for processing as
described previously (96). Material from cleared lysates was probed in immunoblots with NeutrAvidin-
horseradish peroxidase (HRP) (Molecular Probes) and anti-actin (Sigma) or combined with NeutrAvidin
agarose (Molecular Probes) beads to specifically purify biotinylated proteins. Immunoprecipitated ma-
terial was resolved via SDS-PAGE and probed with antibodies specific for Chlamydia Hsp60, TarP (38),
TmeA, or host annexin A2 (Cell Signaling).
Recombinant protein purification. C. trachomatis TmeA and human AHNAK genes were cloned
using GATEWAY technology (Invitrogen) according to the manufacturer’s instructions. For ahnak, the
final 1,000 codons were amplified from HeLa cell cDNA isolated from the ProQuest premade HeLa cDNA
library (Invitrogen) using Q5 high-fidelity (New England BioLabs) DNA polymerase and custom oligonu-
cleotide primers 5=-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCCGTCTGGATTTCGAAGGCCC-3= and 5=-G
GGGACCACTTTGTACAAGAAAGCTGGGTCCTACTCTTTCTTTGTGGAAACTGACAG-3=. Coding sequence for
TmeA was similarly amplified from genomic C. trachomatis L2 DNA using primers SHCT694-4A and
SHCT694-4B (49). PCR products were mobilized into the pDNR221 (Invitrogen) plasmid and subsequently
into pDEST15 and pDEST17 to generate GST- and His-tagged proteins, respectively. Constructs were
verified via DNA sequencing (GENEWIZ).
Tagged constructs were transformed into E. coli BL21-Al, and expression was induced by the addition
of 0.2% (vol/vol) L-arabinose (Sigma-Aldrich). Cell pellets containing GST-tagged proteins were lysed with
BugBuster protein extraction reagent (Novagen) or by passage of suspended pellet in PBS through a
French pressure cell. His-tagged cell pellets were lysed with CelLytic B cell lysis reagent (Sigma-Aldrich).
Affinity chromatography was used to purify the proteins. His-tagged proteins and GST-tagged proteins
were purified using a PrepEase His-tagged protein purification kit (USB Corporation) or GST-Bind resin
(Novagen), respectively, according to the manufacturer’s protocols. All proteins were dialyzed into PBS,
assessed for purity by Coomassie brilliant blue R-250 staining of SDS-PAGE resolved material, and
quantified via Bradford assay (Sigma-Aldrich).
Actin bundling and interactions assays. An actin binding protein biochemistry kit (Cytoskeleton)
was employed utilizing method 3, detecting F-actin bundling activity, with modifications to the manu-
facturer’s protocol (40). F-actin was filamented overnight at 4°C in general actin buffer supplemented
with actin polymerization buffer (5 mM KCl, 200 M MgCl2, and 10 M ATP) to 9% (vol/vol), resulting in
a 21 M F-actin stock solution. Concentrations (20 M) of purified GST-tagged TmeA and AHNAK
underwent a clarification spin at 12,000  g at 4°C for 1 h. Twenty microliters of 21 M F-actin or F-actin
buffer (10% [vol/vol] actin polymerization buffer in general actin buffer) was combined on ice with 10 l
of 20 M clarified test proteins at a 1:1 or 1:1:1 molar ratio of 4 M plus an appropriate amount of PBS
to keep reaction volumes equal between samples. The positive (-actinin) and negative (BSA and GST)
controls were prepared and combined with 20 l of F-actin or F-actin buffer as indicated by the
manufacturer. The protein combinations were incubated at room temperature for 90 min and sedi-
mented by a 12,000  g centrifugation for 15 min at 21°C. Samples were separated into insoluble pellet
and supernatant fractions. Proteins were visualized in material resolved by SDS-PAGE by either Coomas-
sie staining or immunoblotting with AHNAK-specific or TmeA-specific antibodies (49). Relative quantifi-
cation of the amount of F-actin in the supernatant and pellet fractions was conducted using Quantity
One V.4.6 (Bio-Rad).
Actin structure was visualized directly by transmission electron microscopy (TEM). F-actin was
prepared as previously noted and combined with GST-tagged TmeA and AHNAK C1000 in a 1:1 or 1:1:1
molar ratio of 4 M each protein in general actin buffer and processed for visualization by TEM. Samples
were postfixed in 2% osmium tetroxide in 0.1 M phosphate buffer, dehydrated through a series of graded
ethanols, and embedded in EM-bed (Electron Microscopy Sciences, Fort Washington, PA). Eighty-
nanometer sections were cut on a Leica Ultracut-R ultramicrotome (Leica Microsystems Inc., Buffalo
Grove, IL) and stained with uranyl acetate and lead citrate. The grids were viewed at 80 kV on a Philips
CM-10 transmission electron microscope (Koninklijke Philips) and images captured by a Gatan ES1000W
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digital camera (Gatan, Inc., Pleasanton, CA). All images were acquired utilizing Gatan Microscopy Suite
(GMS; Gatan) software. Images were processed using Adobe Photoshop 6.0 (Adobe Systems).
Statistical analysis. All presented data are representative of a minimum of three experiments. Unless
otherwise noted, quantitative data were generated from experiments containing triplicate biological
samples and duplicate technical replicates. Calculation of standard deviations of the means (SD) and
assessment via analysis of variance (ANOVA) or Student’s t test statistical analyses were performed using
GraphPad Prism 6, version 6.04 (GraphPad Software Inc., La Jolla, CA).
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